Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Syngulon and ULB announce the issuance by the USPTO of a first joint patent covering an antibiotic-free selection technology


News provided by

SYNGULON

May 20, 2024, 09:37 ET

Share this article

Share toX

Share this article

Share toX

Syngulon and ULB announce the issuance by the USPTO on March 19, 2024 of US Patent 11,932,672 covering an antibiotic-free selection technology based on bacteriocin/immunity for the production of recombinant protein or pDNA.

SERAING, Belgium and CHARLEROI, Belgium, May 20, 2024 /PRNewswire-PRWeb/ -- Syngulon and ULB announce the issuance by the USPTO on March 19, 2024 of US Patent 11,932,672 covering the use of bacteriocin/immunity for controlled growth of microorganisms.

Antibiotics are widely used as selection agents for the production of a product of interest in microbial cells. However, several drawbacks are associated with antibiotic use, such as the large-scale spreading of antibiotics in the environment. In addition, the sequence coding for the resistance to the antibiotic in the DNA constructs represents an energetic burden for the production host inducing physiological stress negatively affecting the product's yield and quality. This energetic burden is particularly relevant when the resistance-conferring gene is constitutively expressed at a high level.

The USPTO already issued three patents to Syngulon (US Patent 9,333,227/10,188,114/ 11,427,800) for the use of bacteriocin/immunity in any bacteria, yeast or algae for controlled growth of microorganisms. The newly issued US Patent 11,932,672 claims the use of "immunity only" and the control of the selection circuit according to the production fermentation. Professor Laurence Van Melderen (Laboratory of Bacterial Genetics and Physiology, ULB) and Mohamed El Bakkoury (Syngulon) are co-inventors of this patent.

These issued patents are part of a worldwide patent portfolio available for licensing by Syngulon in all fields of use on a non-exclusive base.

The (co)-inventor of these four patents is Dr Philippe Gabant, Co-Founder and Chief Scientific Officer of Syngulon, one of the pioneers in the development of selection technologies. Dr Philippe Gabant is co-inventor of US Patents 5,910,438 / 6,180,407 / 7,176,029 licensed on an exclusive base to Invitrogen for the selection of recombinant plasmids. Dr Philippe Gabant is also co-inventor of US Patent 8,470,580 for production of recombinant protein that has been licensed on a non-exclusive basis to Sanofi Pasteur, GSK, and Merck/MSD. Professor Laurence Van Melderen (Laboratory of Bacterial Genetics and Physiology, ULB) is also the co-inventor of this last patent.

About Syngulon

Syngulon is a synthetic biology startup developing original genetic technologies using bacteriocins, discovered in 1925 by André Gratia in Belgium. They are ribosomally-produced, genetically encoded antimicrobial peptides produced by a wide variety of microorganisms.

Syngulon is a "Startup in the Labs", meaning that we are collaborating with academic partners (e.g. ULB, UCLouvain, KU Leuven, Institute of Tropical Medicine in Belgium, Imperial College, UCL in London, UK, Universidad Complutense Madrid, Spain).

Bacteriocins technologies developed by Syngulon in collaboration with academic partners are solving 3 problems:

1) antibiotic-free technologies for production in a fermentation process (for biopharma, enzymes and industrial biotech)

2) prevention of contamination by using bacteriocins that target the bacteria hurting the production process (e.g. ethanol, cooling towers, feed, animal health)

3) human therapeutic applications of bacteriocins as an alternative to antibiotics in the context of cancer + microbiome modulation + AntiMicrobial Resistance AMR (e.g. MRSA)

About ULB

Université libre de Bruxelles (ULB) is a prominent French-speaking university in Belgium. ULB stands out for its close integration of academic excellence and cutting-edge research. ULB has developed a strategic approach to intellectual property management and valorization, through its Knowledge Transfer Office (ULB-KTO). With the support of the Walloon and Brussels Regions as well as European funds (ERDF), the ULB-KTO team of multidisciplinary advisors assists researchers in the socio-economic valorization of their research results. More information here.

About ULB Laboratory of Bacterial Genetics and Physiology

The Laboratory of Bacterial Genetics and Physiology of ULB has a long-standing expertise in the field of toxin-antitoxin systems and their biotechnological applications. The present US Patent 11,932,672 relies on bacteriocins and their immunity proteins (functionally equivalent to toxin-antitoxin) to produce antibiotic-free recombinant DNA or proteins.

Media Contact

GUY HELIN, SYNGULON, 32 475470708, [email protected], syngulon.com

LinkedIn

SOURCE SYNGULON

Modal title

Logo
Logo
Logo

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.